EUCTR2009-015958-38-ITActive, not recruitingPhase 1
Effect of xantina oxidasi inhibition on left ventricular function and on energetic stores of the haert in patients affected by chronic cardiac insufficiency. - ND
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR0 sites25 target enrollmentStarted: September 15, 2009Last updated:
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 25
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •patients aged between 50 and 90 years old; FE < or equal to 40% documented by ecocardio; uricemia > or equal to 8 mg/die; cardiac insufficiency from about 6 months; steady basal therapy for at least 2 months; NYHA II-III class
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •diseases that may interfere with the study; enrollment in other clinical study;climateric women in hormonal therapy; instable angina or malignant heart block;untreated ipokaliemia; intollerance to allopurinolo; intake of drugs that may induce iperuricemia; patients unable to take part to the study and to underwent the tests
Investigators
Similar Trials
Completed
Phase 4
Do xanthine oxidase inhibitors regress left ventricular hypertrophy in diabetes? A whole new approach to reducing cardiac deathsISRCTN96755104niversity of Dundee (UK)66
Completed
Not Applicable
Does a drug allopurinol reduce heart muscle mass and improve blood vessel function in patients with normal blood pressure and stable angina?ormotensive patients with left ventricular hypertrophy and chronic stable anginaCirculatory SystemComplications and ill-defined descriptions of heart diseaseISRCTN73579730niversity of Dundee (UK)66
Active, not recruiting
Not Applicable
Do xanthine oxidase inhibitors reduce left ventricular hypertrophy and endothelial dysfunction in normotensive patients with chronic stable angina? - Allopurinol in normotensive patients with left ventricular hypertrophyeft ventricular hypertrophyNormotensiveChronic stable anginaMedDRA version: 9.1Level: LLTClassification code 10049773Term: Left ventricular hypertrophyMedDRA version: 9.1Level: LLTClassification code 10049194Term: Stable angina pectorisMedDRA version: 9.1Level: LLTClassification code 10005754Term: Blood pressure normalEUCTR2008-008479-32-GBniversity of Dundee66
Active, not recruiting
Not Applicable
Do Xanthine Oxidase Inhibitors Regress Left ventricular Hypertrophy in Diabetes? - Allopurinol in LVH/DiabetesDiabetes Left Ventricular HypertrophyMedDRA version: 9.1Level: HLTClassification code 10012602Term: Diabetes mellitus (incl subtypes)MedDRA version: 9.1Level: LLTClassification code 10049773Term: Left ventricular hypertrophyEUCTR2008-008485-12-GBniversity of Dundee66
Completed
Not Applicable
Do xanthine oxidase inhibitors reduce both left ventricular hypertrophy and endothelial dysfunction in cardiovascular patients with renal dysfunction?Chronic kidney disease (CKD) and left ventricular hypertrophy (LVH)Circulatory SystemComplications and ill-defined descriptions of heart diseaseISRCTN45773760niversity of Dundee (UK)60